By Héloïse Chaudot 
As consumer demand for preventative healthcare continues to grow, Irish-founded healthspan supplement company ID Formulas is hoping to carve out a niche in the increasingly competitive supplements market by combining clinical research with wearable technology.
Founded by consultant dermatologists Professor Caitriona Ryan and Professor Nicola Ralph alongside healthcare entrepreneur Conor Murphy, the company officially launched its flagship product, Advanced ID, on 25 June. The monthly subscription supplement contains 32 active ingredients formulated to work together across multiple health markers and is designed to support healthy ageing, recovery, and performance.
ID Formulas is positioning itself as a science-led business built around measurable outcomes.
The company says pilot epigenetic testing demonstrated an average reversal in biological clock age of 5.2 years over 12 weeks, while a separate randomised controlled trial reported improvements in areas including cognitive processing, skin hydration, skin barrier function, hair volume and libido.
For Professor Ryan, the company emerged from years of clinical research and conversations with patients seeking evidence-based guidance on supplements.
Having spent much of her career researching systemic inflammation and skin disease, she said she became increasingly aware of a gap in the market between products making broad wellness claims and consumers looking for objective evidence that they were actually working.
That shift, she believes, reflects a broader change within the longevity sector. As wearable technology becomes more mainstream, consumers are increasingly expecting measurable health data rather than relying solely on subjective improvements.
One of the company’s key differentiators is its API integration with WHOOP, allowing users to connect their wearable data with the ID Formulas platform and monitor changes in metrics such as sleep, recovery, and heart rate variability while using the supplement.
“We want to be wearable-agnostic,” Professor Ryan said, adding that the company hopes to expand integrations to other platforms, including Apple Watch, Garmin, and Oura, once the current system has been fully established.
“It’s really important to us, putting our money where our mouth is.”
The company’s commercial strategy is also centred on a direct-to-consumer subscription model, providing recurring revenue while encouraging long-term engagement through personalised health tracking.
ID Formulas comes with Omega-3 soft gel capsules and a water-soluble powder.
Despite launching only recently, Professor Ryan said the business had already exceeded its first two-month sales expectations within 24 hours of launching to an early access waiting list only.
Unlike many health start-ups, ID Formulas has so far been entirely bootstrapped.
The founders plan to launch in the UK within weeks before expanding into the Middle East and the United States, where trademarks have already been secured.
Rather than pursuing traditional venture capital, Professor Ryan said future investment rounds would focus on strategic partners capable of supporting international growth, such as global athletes.
“We want a beautiful cap table,” she said. “We want to be really, really shrewd with our equity.”
The company projects an annual net run rate of €12.8 million by May 2027 based on 5,000 active subscribers, although Professor Ryan said she believes the business is capable of more than doubling those figures following stronger-than-expected demand at launch.
For ID Formulas, however, the long-term ambition extends beyond supplements. As consumers increasingly seek personalised, data-driven healthcare, the founders believe wearable technology and measurable outcomes will play a defining role in the future of the longevity industry.
